dehydrocorydalin has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Huang, H; Huang, Y; Wang, S; Zheng, G | 1 |
| Bao, J; Chen, L; Chen, X; Dang, Y; Fu, S; Huang, M; Wang, Y; Xu, Z | 1 |
2 other study(ies) available for dehydrocorydalin and Breast Neoplasms
| Article | Year |
|---|---|
Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, SCID | 2020 |
Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Corydalis; Cysteine Proteinase Inhibitors; DNA Fragmentation; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Humans; Membrane Potential, Mitochondrial; Oligopeptides; Phytotherapy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2 | 2012 |